Biomarker Tests: From Discovery to Clinical Validation
By Dr. Zubair Khalid, DVM, MS, PhD ·
Introduction to Biomarker Tests
What is a Biomarker Test?
A biomarker test is a standardized analytical procedure that measures a defined biological molecule, cellular characteristic, or physiological parameter—the biomarker—and interprets the result to inform clinical decision-making. The biomarker itself is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. A biomarker test transforms a raw measurement into a clinically actionable result through a validated algorithm, reference range, or threshold.
The clinical utility of a biomarker test depends on the context of use. A diagnostic test identifies the presence of a disease or condition. A prognostic test stratifies patients by their likely disease course independent of therapy. A predictive test identifies patients who are more likely to respond to a specific treatment. These categories are not mutually exclusive; a single biomarker may serve multiple roles depending on the clinical question and the population in which it is applied.
The development of a biomarker test follows a defined pipeline: discovery, analytical validation, clinical validation, regulatory approval, and clinical implementation. Each stage has distinct scientific requirements, failure modes, and standards of evidence. This article provides a mechanistic and methodological overview of that pipeline, with emphasis on the experimental design decisions and statistical principles that determine whether a candidate biomarker becomes a clinically useful test or remains a research finding.
Types of Biomarkers and Their Clinical Utility
Biomarkers are commonly classified by their molecular nature and their clinical application. Molecular biomarkers include DNA sequence variants, epigenetic modifications, RNA transcripts, proteins, and metabolites. Cellular biomarkers include circulating tumor cells, immune cell subsets, and other enumerable cell populations. Physiological biomarkers include imaging parameters, electrical signals, and hemodynamic measurements.
The clinical utility of a biomarker test is defined by its intended use. Screening biomarkers are applied to asymptomatic populations to detect early disease. Diagnostic biomarkers confirm or exclude a suspected condition. Staging biomarkers classify disease severity. Prognostic biomarkers predict disease recurrence or survival. Predictive biomarkers forecast treatment response. Monitoring biomarkers track disease progression or treatment effect over time. Pharmacodynamic biomarkers measure the biological effect of a drug. Finally, surrogate endpoints are biomarkers intended to substitute for a clinical endpoint in clinical trials.
The distinction between a biomarker and a biomarker test is critical. A biomarker is a biological finding; a biomarker test is the reproducible, standardized measurement of that finding with defined performance characteristics. A protein that is differentially expressed in tumor tissue is a candidate biomarker. The ELISA-based assay that quantifies that protein in serum with a defined limit of detection, precision, and clinical threshold is a biomarker test. This distinction underlies the entire validation framework discussed below.
Biomarker Discovery: Omics Technologies and Approaches
Genomics and Transcriptomics
Genomic biomarker discovery identifies DNA sequence variants, structural variants, or epigenetic modifications associated with disease. Whole-genome sequencing and whole-exome sequencing are used to identify rare variants with large effect sizes, while genome-wide association studies (GWAS) identify common variants with modest effect sizes. For germline variants, DNA is typically extracted from peripheral blood or saliva. For somatic variants in cancer, tumor tissue is required, and the variant allele frequency must be interpreted in the context of tumor purity and copy number status.
Transcriptomic discovery uses RNA sequencing (RNA-seq) or microarrays to identify differentially expressed genes, splice variants, or non-coding RNAs. RNA-seq provides digital read counts with a broad dynamic range, enabling detection of low-abundance transcripts. Typical protocols involve poly-A selection or ribosomal RNA depletion, cDNA synthesis, adapter ligation, and sequencing to a depth of 20–50 million reads per sample for differential expression analysis. Data analysis includes alignment to a reference genome, quantification of transcript abundance, and statistical testing for differential expression using tools such as DESeq2 or edgeR, which model count data with negative binomial distributions.
A critical experimental design consideration in transcriptomic discovery is the choice of tissue or biofluid. Tumor tissue is the most direct source of disease-relevant transcripts but requires invasive biopsy. Peripheral blood mononuclear cells, plasma, or serum may be more accessible but contain transcripts from heterogeneous cell populations. The cellular composition of blood varies between individuals and can confound differential expression results. Computational deconvolution methods can estimate cell-type proportions from bulk RNA-seq data, but these methods rely on reference signatures that may not be accurate across all conditions.
Proteomics and Metabolomics
Proteomic biomarker discovery aims to identify proteins that are differentially abundant between disease and control groups. Mass spectrometry (MS)-based approaches, including label-free quantification and isobaric tagging (TMT or iTRAQ), enable simultaneous identification and quantification of thousands of proteins. A typical bottom-up proteomics workflow involves protein extraction, enzymatic digestion with trypsin, peptide separation by liquid chromatography, and tandem mass spectrometry. Data-dependent acquisition (DDA) selects the most abundant precursor ions for fragmentation, while data-independent acquisition (DIA) systematically fragments all precursor ions in a defined mass window, providing more complete coverage and better reproducibility.
The dynamic range of the proteome presents a major challenge. In plasma, albumin and immunoglobulins constitute more than 70% of total protein mass, masking lower-abundance proteins. Depletion of high-abundance proteins using affinity columns targeting albumin and IgG can improve detection of mid-abundance proteins, but this step introduces potential bias and technical variability. Alternatively, fractionation at the peptide level, such as high-pH reversed-phase fractionation, increases analytical depth without the bias of protein-level depletion.
Metabolomic discovery uses nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry coupled to liquid or gas chromatography. NMR is highly reproducible and quantitative but has limited sensitivity, detecting metabolites in the micromolar range. Mass spectrometry-based metabolomics achieves nanomolar sensitivity but requires careful attention to ion suppression, matrix effects, and batch effects. Targeted metabolomics quantifies a predefined panel of metabolites using stable isotope-labeled internal standards, while untargeted metabolomics aims to detect and identify all detectable metabolites, with annotation rates typically below 30% of detected features.
Integrative Multi-Omics Strategies
No single omics layer captures the full biological complexity of disease. Genomic variants may not alter transcript abundance; transcript abundance may not correlate with protein abundance due to post-transcriptional regulation; and protein abundance may not reflect enzymatic activity due to post-translational modifications. Integrative multi-omics approaches combine data from multiple layers to identify biomarkers that are robust across biological levels and to elucidate mechanism.
A common integration strategy is to use genomic variants as anchors and test whether they associate with transcript, protein, or metabolite levels. Expression quantitative trait loci (eQTL) analysis identifies genetic variants that regulate gene expression. Protein quantitative trait loci (pQTL) analysis extends this concept to protein levels. These analyses can establish causal relationships between genetic variants and molecular phenotypes, strengthening the biological plausibility of candidate biomarkers.
Statistical integration methods include concatenation-based approaches, which combine all features into a single matrix and apply machine learning; transformation-based approaches, which project data into a lower-dimensional space using methods such as canonical correlation analysis or multi-omics factor analysis; and network-based approaches, which construct molecular interaction networks and identify modules associated with disease. The choice of method depends on the biological question and the structure of the data. For biomarker discovery, the goal is not merely to integrate data but to identify a parsimonious set of features that can be measured reliably in a clinical laboratory.
Analytical Validation: Ensuring Reproducible Measurement
Assay Development and Calibration
Analytical validation establishes that the assay measures the biomarker accurately, precisely, and reproducibly under defined conditions. The first step is assay development, which involves selecting the analytical platform, defining the reagents, and optimizing the protocol. For protein biomarkers, the ELISA Test is a common platform because it provides high sensitivity, specificity, and throughput. A sandwich ELISA uses a capture antibody immobilized on a microtiter plate and a detection antibody conjugated to an enzyme such as horseradish peroxidase. The typical protocol involves blocking with bovine serum albumin (1–5% w/v in PBS) or casein, incubation with standards and samples, washing with PBS containing 0.05% Tween-20, and detection with a chromogenic substrate such as tetramethylbenzidine. The limit of detection is typically in the picogram to nanogram per milliliter range.
For low-abundance proteins, digital ELISA platforms such as Simoa achieve femtomolar sensitivity by isolating individual enzyme-labeled immunocomplexes in femtoliter-volume wells. For protein confirmation and characterization, the Western Blot Test remains valuable, particularly for detecting specific isoforms or post-translational modifications. Western blotting involves SDS-PAGE separation, transfer to a nitrocellulose or PVDF membrane, blocking, primary antibody incubation, secondary antibody incubation, and chemiluminescent detection.
Calibration establishes the relationship between the measured signal and the analyte concentration. A calibration curve is generated using known concentrations of the analyte, typically prepared by serial dilution of a purified standard. The curve is fitted to a four-parameter logistic (4PL) or five-parameter logistic (5PL) model, which accounts for the sigmoidal relationship between concentration and signal. The calibration range must bracket the expected clinical range, and the lower limit of quantification (LLOQ) must be below the clinical decision threshold.
Quality Control and Reference Standards
Quality control (QC) ensures that the assay performs within defined specifications during routine use. QC samples at low, medium, and high concentrations are included in each run, and their measured values are plotted on Levey-Jennings charts. Westgard rules are applied to detect systematic errors, such as shifts or trends, and random errors, such as increased variability. A run is rejected if QC values fall outside predefined acceptance criteria, typically ±2 standard deviations for warning limits and ±3 standard deviations for rejection limits.
Reference standards are essential for calibration and for comparing results across laboratories. A reference standard is a material with a known concentration of the analyte, ideally certified by a reference laboratory. For many protein biomarkers, international reference standards are available from the World Health Organization (WHO) or the National Institute for Biological Standards and Control (NIBSC). These standards are assigned international units, enabling harmonization of results across different assays and laboratories.
Precision is assessed by measuring the same sample multiple times within a single run (intra-assay precision) and across multiple runs, days, and operators (inter-assay precision). The coefficient of variation (CV) is calculated as the standard deviation divided by the mean, expressed as a percentage. Acceptance criteria typically require CVs below 10–15% for immunoassays and below 20% for more complex assays such as mass spectrometry-based proteomics. Accuracy is assessed by measuring samples with known concentrations, such as reference standards or spiked samples, and calculating the percent recovery.
Clinical Validation: Establishing Diagnostic or Prognostic Value
Study Design: Retrospective vs. Prospective
Clinical validation demonstrates that the biomarker test accurately predicts the clinical outcome of interest. The study design must match the intended clinical use. Retrospective studies use archived samples from patients with known outcomes. These studies are efficient and can be completed quickly, but they are susceptible to selection bias, sample degradation, and incomplete clinical data. Prospective studies enroll patients before the outcome occurs, collect samples according to a predefined protocol, and follow patients for the outcome. Prospective designs provide higher-quality evidence but require more time and resources.
The choice of study population is critical. A diagnostic biomarker test should be evaluated in a population that resembles the intended-use population, including patients with the disease, patients with conditions that mimic the disease, and healthy controls. A prognostic biomarker test should be evaluated in a cohort of patients with the disease who are followed longitudinally for outcomes such as recurrence or death. A predictive biomarker test requires a randomized controlled trial in which patients are assigned to treatment or control, and the biomarker is measured before treatment. The interaction between biomarker status and treatment effect is then tested.
Sample size calculations must account for the expected effect size, the prevalence of the outcome, and the desired statistical power. For a biomarker with an area under the receiver operating characteristic curve (AUC) of 0.80, a sample size of approximately 50 cases and 50 controls provides 80% power to detect a significant difference from an AUC of 0.50 at a significance level of 0.05. For prognostic biomarkers with time-to-event outcomes, the sample size depends on the number of events, not the total number of patients.
Statistical Metrics: Sensitivity, Specificity, AUC
The diagnostic performance of a biomarker test is characterized by sensitivity and specificity. Sensitivity is the proportion of patients with the disease who test positive. Specificity is the proportion of patients without the disease who test negative. These metrics depend on the threshold used to define a positive result. The receiver operating characteristic (ROC) curve plots sensitivity against 1-specificity across all possible thresholds. The area under the ROC curve (AUC) summarizes the overall discriminatory ability of the test, with 0.5 indicating no discrimination and 1.0 indicating perfect discrimination.
The choice of threshold depends on the clinical context. For a screening test, high sensitivity is prioritized to avoid missing cases, accepting lower specificity. For a confirmatory diagnostic test, high specificity is prioritized to avoid false positives. The optimal threshold can be identified using the Youden index, which maximizes sensitivity plus specificity minus one, or by weighting the costs of false positives and false negatives.
For prognostic biomarkers, the concordance index (C-index) is a common metric. The C-index estimates the probability that, for a randomly selected pair of patients, the patient who experiences the event earlier has a higher predicted risk. A C-index of 0.5 indicates no predictive ability, and 1.0 indicates perfect prediction. The C-index is analogous to the AUC for time-to-event data.
Calibration is equally important as discrimination. A well-calibrated test produces predicted probabilities that match observed outcomes. Calibration is assessed by plotting predicted versus observed outcomes in deciles of predicted risk and by calculating the calibration slope, which should be close to 1.0. A test with excellent discrimination but poor calibration can mislead clinical decisions.
Regulatory and Ethical Considerations for Biomarker Tests
Regulatory Pathways (FDA, EMA, CLIA)
In the United States, biomarker tests are regulated by the Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA). The regulatory pathway depends on whether the test is marketed as a kit or performed as a laboratory-developed test (LDT). In vitro diagnostic (IVD) kits require FDA premarket approval (PMA) or 510(k) clearance, depending on the risk classification. PMA requires demonstration of analytical and clinical validity through clinical studies. The 510(k) pathway requires demonstration of substantial equivalence to a legally marketed predicate device.
Laboratory-developed tests are developed and performed within a single laboratory. Historically, LDTs were regulated under CLIA, which requires laboratories to demonstrate analytical validity but not clinical validity. However, the FDA has announced its intention to regulate LDTs as medical devices, requiring premarket review for high-risk tests. The regulatory landscape for LDTs is evolving, and researchers developing novel biomarker tests should consult current FDA guidance.
In the European Union, in vitro diagnostic medical devices are regulated under the In Vitro Diagnostic Regulation (IVDR), which came into full application in 2022. The IVDR classifies IVDs into four risk classes (A, B, C, D), with higher-risk tests requiring involvement of a notified body for conformity assessment. Clinical evidence requirements include analytical performance, clinical performance, and scientific validity.
Ethical and Social Implications
Biomarker tests raise ethical issues related to informed consent, privacy, and incidental findings. Informed consent for biomarker research must disclose the purpose of the research, the types of analyses to be performed, the potential for incidental findings, and the plans for return of results. When biomarker tests are used clinically, patients must understand the implications of the test result, including the possibility of false positives and false negatives.
Incidental findings are results that are unrelated to the clinical question but may have health implications. For example, genomic sequencing performed to identify a disease-causing variant may reveal a pathogenic variant in a gene associated with a different condition. The American College of Medical Genetics and Genomics (ACMG) recommends that laboratories report pathogenic variants in a defined list of 73 genes associated with medically actionable conditions, regardless of the indication for testing. Researchers must have a plan for managing incidental findings, including whether and how to return results to participants.
Privacy and data security are critical concerns for biomarker tests that generate sensitive health information. Genetic and genomic data are particularly sensitive because they are unique to the individual and can reveal information about family members. Researchers and clinicians must comply with applicable privacy regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union.
Clinical Implementation and Utility
Companion Diagnostics and Theranostics
A companion diagnostic (CDx) is a biomarker test that is required for the safe and effective use of a corresponding therapeutic product. The test identifies patients who are most likely to benefit from the drug or who are at increased risk of serious adverse effects. Companion diagnostics are developed in parallel with the therapeutic product and are typically approved by the FDA simultaneously.
Examples of companion diagnostics include tests for HER2 amplification or overexpression, which are required before treatment with trastuzumab in HER2-positive breast cancer; EGFR mutation testing, which is required before treatment with EGFR tyrosine kinase inhibitors such as erlotinib or osimertinib in non-small cell lung cancer; and BRCA1/BRCA2 mutation testing, which is required before treatment with PARP inhibitors such as olaparib in ovarian cancer. These tests are typically performed on tumor tissue using methods such as fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), or next-generation sequencing (NGS).
Theranostics refers to the combination of a diagnostic test and a therapeutic agent, where the diagnostic identifies patients who will respond to the therapy. The term is most commonly used in nuclear medicine, where a radiolabeled compound is used for both imaging and therapy. For example, gallium-68 DOTATATE PET imaging identifies neuroendocrine tumors expressing somatostatin receptors, and lutetium-177 DOTATATE is used for peptide receptor radionuclide therapy in patients with positive scans.
Clinical Decision Support and Guidelines
The integration of biomarker tests into clinical practice requires clinical decision support tools that present test results in a context that facilitates interpretation. Clinical practice guidelines, developed by professional societies such as the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO), provide recommendations for the use of biomarker tests based on the strength of evidence. Guidelines typically classify recommendations by the level of evidence, ranging from category 1 (high-level evidence, uniform consensus) to category 3 (major disagreement).
Reimbursement is a major barrier to clinical implementation. In the United States, Medicare coverage for biomarker tests is determined by local and national coverage determinations. Coverage decisions consider whether the test is reasonable and necessary for the diagnosis or treatment of illness or injury. Private payers may follow Medicare coverage decisions or develop their own policies. The evidence required for coverage includes analytical validity, clinical validity, and clinical utility—demonstrating that the test improves health outcomes.
Common Pitfalls and Misinterpretations in Biomarker Research
Overfitting and Multiple Testing
Overfitting occurs when a statistical model is too complex for the amount of data, capturing noise rather than true biological signal. In biomarker discovery, overfitting is common when thousands of features are measured in a small number of samples. A model that perfectly classifies the training data may perform poorly on independent data. The risk of overfitting increases with the number of features tested and decreases with sample size.
Multiple testing is a related problem. When thousands of hypotheses are tested simultaneously, the probability of false positives increases. The Bonferroni correction controls the family-wise error rate by dividing the significance threshold by the number of tests, but it is overly conservative for correlated omics data. The false discovery rate (FDR), estimated using the Benjamini-Hochberg procedure, controls the expected proportion of false positives among rejected hypotheses and is the standard approach in omics research. For a typical transcriptomics experiment testing 20,000 genes, an FDR of 0.05 is commonly used.
The most effective protection against overfitting is independent validation. Candidate biomarkers identified in a discovery cohort must be tested in an independent cohort using a pre-specified assay and analysis plan. The validation cohort should be drawn from a different population, collected at a different time, and analyzed in a different laboratory to ensure generalizability.
Confounding and Bias
Confounding occurs when a variable is associated with both the biomarker and the outcome, creating a spurious association. For example, age is associated with many biomarkers and with many diseases. If cases and controls differ in age, the biomarker may appear to be associated with disease when it is actually associated with age. Confounding can be addressed through study design (matching, restriction) or analysis (stratification, multivariable adjustment).
Bias is a systematic error that distorts the true association. Selection bias occurs when the study population is not representative of the target population. In biomarker studies, selection bias can arise from differential recruitment of cases and controls, differential availability of samples, or differential loss to follow-up. Information bias occurs when measurement errors are systematically different between groups. In biomarker studies, information bias can arise from differences in sample collection, processing, or storage between cases and controls.
Preanalytical variables are a common source of bias in biomarker studies. The time from sample collection to processing, the temperature during storage, the number of freeze-thaw cycles, and the type of collection tube can all affect biomarker levels. For example, plasma and serum differ in the levels of many proteins and metabolites. Hemolysis, which releases intracellular contents, can dramatically alter measured levels of potassium, lactate dehydrogenase, and other analytes. Standardized protocols for sample collection, processing, and storage are essential for minimizing preanalytical variability.
Reproducibility and Reporting Standards
Poor reproducibility is a major problem in biomarker research. Many published biomarker findings cannot be replicated in independent studies. Causes include inadequate sample size, overfitting, lack of standardized assays, and selective reporting of positive results. The scientific community has developed reporting standards to improve transparency and reproducibility. The Standards for Reporting of Diagnostic Accuracy Studies (STARD) provide guidelines for reporting diagnostic accuracy studies. The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) provide guidelines for reporting prognostic biomarker studies. The Minimum Information About a Microarray Experiment (MIAME) and Minimum Information About a Proteomics Experiment (MIAPE) provide guidelines for reporting omics data.
Pre-registration of biomarker studies, in which the study design, analysis plan, and primary endpoints are specified before data collection, can reduce the risk of selective reporting and p-hacking. Data sharing, in which raw data are deposited in public repositories, enables independent verification and secondary analysis. The National Institutes of Health (NIH) and many journals now require data sharing for funded research.
Future Directions and Emerging Technologies
Liquid Biopsy and Circulating Biomarkers
Liquid biopsy refers to the analysis of tumor-derived material in peripheral blood or other body fluids, providing a minimally invasive alternative to tissue biopsy. Circulating tumor DNA (ctDNA) is fragmented DNA released from tumor cells through apoptosis, necrosis, or active secretion. ctDNA can be detected and quantified using digital PCR or next-generation sequencing. The variant allele fraction of ctDNA is typically very low, ranging from 0.01% to several percent, requiring ultrasensitive detection methods.
ctDNA analysis has multiple clinical applications. In early-stage cancer, ctDNA can be used for minimal residual disease (MRD) detection after surgery, identifying patients at high risk of recurrence who may benefit from adjuvant therapy. In metastatic cancer, ctDNA can be used to monitor treatment response and to detect resistance mutations that emerge during therapy. For example, detection of the EGFR T790M mutation in ctDNA identifies patients with non-small cell lung cancer who have developed resistance to first-generation EGFR inhibitors and who may benefit from osimertinib.
Circulating tumor cells (CTCs) are intact tumor cells that have entered the bloodstream. CTCs are enumerated using methods such as the CellSearch system, which uses immunomagnetic capture of epithelial cell adhesion molecule (EpCAM)-positive cells. CTC enumeration has prognostic value in metastatic breast, prostate, and colorectal cancer. Beyond enumeration, CTCs can be characterized for protein expression, genomic alterations, and drug sensitivity, providing a dynamic view of tumor biology.
Extracellular vesicles, including exosomes, are lipid bilayer-enclosed particles released by cells that carry proteins, RNA, and DNA. Exosomes are abundant in blood and other body fluids and may provide a rich source of biomarkers. However, the isolation and characterization of exosomes is technically challenging, and the clinical utility of exosomal biomarkers remains to be established. The Flow Cytometry Test is commonly used to characterize extracellular vesicle populations, though the small size of exosomes (30–150 nm) is below the detection limit of conventional flow cytometers, requiring specialized high-sensitivity instruments.
AI and Machine Learning in Biomarker Discovery
Artificial intelligence (AI) and machine learning (ML) methods are increasingly used in biomarker discovery to identify patterns in high-dimensional data, integrate multi-omics datasets, and develop predictive models. Deep learning methods, including convolutional neural networks (CNNs) and transformer-based architectures, can learn complex, non-linear relationships from raw data. In medical imaging, deep learning models can identify radiographic features associated with disease that are not visible to the human eye.
In genomics, deep learning models such as DeepSEA and Basenji predict the functional effects of non-coding variants by learning regulatory patterns from DNA sequence. In proteomics, machine learning methods are used to predict peptide fragmentation patterns, improve protein identification, and quantify proteins from DIA data. In metabolomics, machine learning is used for peak picking, compound identification, and pathway analysis.
The application of AI to biomarker discovery raises important methodological concerns. Deep learning models require large training datasets, which are often unavailable in biomarker research. Transfer learning, in which a model pre-trained on a large dataset is fine-tuned on a smaller dataset, can partially address this limitation. Model interpretability is another concern; clinicians are reluctant to act on predictions from a "black box" model. Methods such as SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) provide post-hoc explanations of model predictions, but these explanations may not capture the true decision process of the model.
Summary and Practical Guidance for Researchers
Key Takeaways
The development of a biomarker test is a rigorous, multi-stage process that requires distinct scientific skills and standards of evidence at each stage. The following principles are essential for success:
- Define the clinical context of use before starting discovery. The intended use determines the study design, the patient population, the sample type, and the performance thresholds.
- Use standardized protocols for sample collection, processing, and storage. Preanalytical variability is a leading cause of irreproducible biomarker findings.
- Apply appropriate statistical corrections for multiple testing. The false discovery rate is the standard approach in omics research.
- Validate findings in independent cohorts. A biomarker that cannot be replicated is not a biomarker.
- Distinguish analytical validation from clinical validation. Analytical validation establishes that the assay measures what it claims to measure; clinical validation establishes that the measurement predicts the outcome.
- Consider regulatory requirements early in development. The regulatory pathway affects the type and amount of evidence required.
- Report results according to established standards. STARD, REMARK, and related guidelines improve transparency and reproducibility.
Checklist for Biomarker Test Development
- Define the clinical question and context of use. Specify the target population, the intended use (screening, diagnosis, prognosis, prediction), and the clinical decision that will be informed by the test result.
- Select the biomarker type and measurement platform. Consider the biological plausibility, the availability of samples, the required sensitivity and specificity, and the cost and throughput of the platform.
- Design the discovery study. Define the sample size, the inclusion and exclusion criteria, the sample collection protocol, and the statistical analysis plan.
- Identify candidate biomarkers. Apply appropriate statistical methods for high-dimensional data, with correction for multiple testing.
- Develop and optimize the assay. Establish the calibration curve, the limit of detection, the limit of quantification, and the precision and accuracy of the assay.
- Perform analytical validation. Assess intra-assay and inter-assay precision, accuracy, linearity, and robustness to variations in reagents, operators, and instruments.
- Perform clinical validation. Evaluate sensitivity, specificity, AUC, and calibration in an independent cohort that resembles the intended-use population.
- Assess clinical utility. Demonstrate that the test improves clinical outcomes or informs clinical decisions in a way that justifies its use.
- Obtain regulatory approval. Submit the evidence package to the appropriate regulatory authority, following the applicable pathway for the test type and jurisdiction.
- Implement in clinical practice. Develop clinical decision support tools, train clinicians, and address reimbursement and quality assurance.
Frequently Asked Questions
What is a biomarker test?
A biomarker test is a standardized analytical procedure that measures a biological molecule, cellular characteristic, or physiological parameter and interprets the result to inform clinical decision-making. The test includes the assay, the calibration and quality control procedures, the threshold for positivity, and the algorithm for interpreting the result in the clinical context.
What are the different types of biomarker tests?
Biomarker tests are classified by their clinical application: screening tests detect disease in asymptomatic populations; diagnostic tests confirm or exclude a suspected condition; prognostic tests predict disease course; predictive tests forecast treatment response; monitoring tests track disease progression or treatment effect; and pharmacodynamic tests measure the biological effect of a drug. Companion diagnostics are a specific type of predictive test that is required for the safe and effective use of a corresponding therapy.
How are biomarker tests developed?
Biomarker tests are developed through a pipeline that includes discovery, analytical validation, clinical validation, regulatory approval, and clinical implementation. Discovery uses high-throughput omics technologies to identify candidate biomarkers. Analytical validation establishes that the assay measures the biomarker accurately and reproducibly. Clinical validation demonstrates that the test predicts the clinical outcome of interest. Regulatory approval and clinical implementation translate the validated test into clinical practice.
What is the difference between analytical and clinical validation?
Analytical validation establishes that the assay measures the biomarker accurately, precisely, and reproducibly. It includes assessment of sensitivity, specificity, precision, accuracy, linearity, and robustness. Clinical validation establishes that the test result is associated with the clinical outcome of interest. It includes assessment of diagnostic sensitivity and specificity, AUC, calibration, and clinical utility. Analytical validation is necessary but not sufficient for clinical validity.
What are common pitfalls in biomarker research?
Common pitfalls include overfitting, multiple testing without appropriate correction, confounding, bias, inadequate sample size, lack of independent validation, poor preanalytical handling, and selective reporting. These pitfalls can be avoided by careful study design, standardized protocols, appropriate statistical methods, independent validation, and adherence to reporting standards.
How are biomarker tests approved for clinical use?
In the United States, biomarker tests are regulated by the FDA and CMS under CLIA. IVD kits require FDA premarket approval or 510(k) clearance. Laboratory-developed tests are regulated under CLIA, though the FDA has announced plans to regulate them as medical devices. In the European Union, IVDs are regulated under the IVDR, which classifies tests by risk and requires conformity assessment by notified bodies for higher-risk tests.
What are some examples of FDA-approved biomarker tests?
Examples include HER2 testing by IHC or FISH to guide trastuzumab therapy in breast cancer; EGFR mutation testing by PCR or NGS to guide EGFR inhibitor therapy in non-small cell lung cancer; BRCA1/BRCA2 mutation testing to guide PARP inhibitor therapy in ovarian cancer; KRAS mutation testing to guide anti-EGFR therapy in colorectal cancer; and PD-L1 IHC to guide immune checkpoint inhibitor therapy in multiple cancer types. These tests are approved as companion diagnostics in conjunction with the corresponding therapeutic products.
Key Takeaways
- A biomarker test is a standardized measurement of a biological characteristic with defined analytical and clinical performance, used to inform clinical decisions.
- Biomarker discovery uses genomics, transcriptomics, proteomics, and metabolomics, with careful attention to experimental design, sample handling, and statistical correction for multiple testing.
- Analytical validation establishes that the assay measures the biomarker accurately and reproducibly, including assessment of precision, accuracy, sensitivity, and robustness.
- Clinical validation demonstrates that the test predicts the clinical outcome, using appropriate study designs and statistical metrics such as sensitivity, specificity, and AUC.
- Regulatory approval requires demonstration of analytical and clinical validity, with pathways varying by jurisdiction and test type.
- Common pitfalls include overfitting, confounding, bias, lack of independent validation, and poor preanalytical handling; these can be mitigated by rigorous study design and adherence to reporting standards.
- Emerging technologies, including liquid biopsy and AI-based analysis, are expanding the possibilities for biomarker discovery and clinical application, but require the same rigorous validation standards as established methods.
Further Reading
- Smedemark SA et al. Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care. The Cochrane database of systematic reviews. 2022. PubMed 36250577
- Hayes DF. Biomarker validation and testing. Molecular oncology. 2015. PubMed 25458054
- Mete O et al. Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management. Endocrine pathology. 2024. PubMed 39579327
- Kravchuk AP et al. Urine-Based Biomarker Test Uromonitor(®) in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer-A Systematic Review and Meta-Analysis of Diagnostic Test Performance. Cancers. 2024. PubMed 38398144
- Dreyer T et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. European urology. 2025. PubMed 40280776
- Hu S, Yu H, Gao J. The pTau217/Aβ(1-42) plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease. Drug discoveries & therapeutics. 2025. PubMed 40582836